Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABSI
SELLAbsci Corporation · Healthcare · United States · $1.3B · Avg Vol: $49M/d
COMPANY DESCRIPTION
Absci Corporation is an AI-powered drug discovery company that utilizes its 'wet lab + dry lab' platform to discover novel biotherapeutics and accelerate drug development. It integrates generative AI with high-throughput experimental biology to design, validate, and manufacture new biologics faster and more effectively than traditional methods. The company is revolutionizing the biopharmaceutical discovery process by leveraging advanced AI and synthetic biology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.7M | 5.7M | 4.5M | 2.8M | -21.3% | 1.8M | 5.7M | — | 102.5% |
| EPS | -1.15 | -1.20 | -0.94 | -0.84 | — | -0.81 | -0.78 | -0.62 | — |
| Shares | 92.4M | 93.1M | 115.4M | 151.5M | +64.0% | 169.4M | — | — | — |
| Debt | 23.0M | 15.9M | 10.0M | 5.3M | -38.7% | 4.4M | — | — | — |
| Equity | 274.4M | 176.2M | 179.1M | 189.4M | -11.6% | — | — | — | — |
| Op CF | -81.3M | -64.6M | -72.4M | -92.9M | — | -97.4M | — | — | — |
| Inv CF | -127.0M | 81.9M | -41.6M | -50.2M | — | — | — | — | — |
| Fin CF | 5.2M | -4.5M | 82.5M | 105.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABSI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABSI | Absci Corporation(you) | $1.3B | 22 | SELL |
| ARDX | Ardelyx, Inc. | $1.2B | 22 | SELL |
| MNKD | MannKind Corporation | $1.3B | 23 | SELL |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.3B | 21 | SELL |
| SVRA | Savara Inc. | $1.1B | 19 | STRONG SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 19 | STRONG SELL |
| TYRA | Tyra Biosciences, Inc. | $1.8B | 21 | SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 21 | SELL |
| JANX | Janux Therapeutics, Inc. | $935M | 24 | SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%